Harrow expands VEVYE Access for All program to Klarity-C patients

(Image Credit: AdobeStock/Sviatoslav Kovtun)

Harrow is expanding its VEVYE Access for All campaign to include patients who use compounded cyclosporine 0.1% (Klarity-C, ImprimisRx) for dry eye and are interested in switching to cyclosporine ophthalmic solution 0.1% (VEVYE, Harrow). With this program, patients who use Klarity-C can convert their prescription to VEVYE for a flat rate of $59 per bottle, including refills. They are also eligible for additional program benefits, such as free shipping and a no-questions-asked money-back guarantee.¹

Interested patients can transfer their prescription to PhilRx beginning today and can be done in less than 5 minutes, according to Harrow. Patients can also choose to use insurance coverage or to pay cash, depending on which is best for them at the time.

“We are pleased to make VEVYE accessible and affordable to Klarity-C patients,” Mark L. Baum, CEO of Harrow, said in a press release. “The secret to the success of VEVYE Access for All is simple: lower costs to patients and eliminate the requirement for prescribers to endure the burden of access obstacles like prior authorizations and step therapy. The result is twofold: dry eye patients receive what their doctor prescribes at an affordable price; and for doctors and their staff, choosing VEVYE is an absolute no‑brainer.”

On March 17, Harrow launchedVEVYE Access for All, an initiative poised to make it easier for patients to access dry eye therapy. By partnering with PhilRx, a national mail-order pharmacy, Harrow hopes to expedite prescription fulfillment via a flat-rate refill program as well as no prior authorization requirement. The program includes free delivery to patients’ homes, as little as $0 cost for the first prescription of cyclosporine 0.1% (with insurance), and $59 refills for eligible patients.²

“Pharmaceutical companies have long made promises to tackle the access barriers my colleagues and I encounter when advocating for our patients – especially in the realm of dry eye treatments. Harrow, a company that has consistently brought meaningful innovation to my practice, has delivered once again with VEVYE Access For All,” Alice Epitropoulos, MD, FACS, partner and cofounder of the Eye Center of Columbus, said in a press release. “I often prescribed Klarity-C because it provided exceptional value to my patients, particularly those without insurance or with limited coverage. Now, being able to offer VEVYE at that same affordable price point to some of my dry eye disease patients – without the usual insurance hassles – is a game changer. This is true price transparency and accessibility that simplifies care and supports what matters most: better outcomes.”

VEVYE Access for All began in an attempt to reduce barriers to dry eye therapy, and Harrow plans to continue this mission by expanding the campaign to include all pharmacy networks over time. The hope is that quick prescription processing and a flat refill rate will help patients find relief quickly.

“The value proposition here is undeniable,” Mitchell Jackson, MD, Founder/Medical director of Jacksoneye and a pioneer in refractive surgery and dry eye management, said in a press release. “My colleagues in ophthalmology and optometry already know about VEVYE’s extraordinary clinical benefits. But how often do we see a pharmaceutical company actually lower costs and pass those savings directly to the patients – all while removing the insurance hurdles that have burdened our practices? Only Harrow. No prior authorizations or step therapy requirements, no surprise bills – just straightforward, reliable access to an excellent medication. It’s the kind of model our healthcare system should be moving toward.”

To learn more about the VEVYE Access for All program, including full terms and conditions for eligibility, visit the VEVYE website. Klarity C prescribers who have questions about transitioning to VEVYE or leveraging the Vevye Access for All program can call (855) 977-0975 or e-mail mdsupport@usephil.com for further assistance.

References:

1. Harrow Expands VEVYE Access for All Program to ImprimisRx’s Klarity-C Patients. BusinessWire. Press release. Published April 10, 2025. Accessed April 10, 2025. https://www.businesswire.com/news/home/20250410793815/en/Harrow-Expands-VEVYE-Access-for-All-Program-to-ImprimisRxs-Klarity-C-Patients

2. Maharjan EK. Harrow launches partnership with PhilRx to expand access to VEVYE. Optometry Times. Published March 17, 2025. Accessed April 10, 2025. https://www.optometrytimes.com/view/harrow-launches-partnership-with-philrx-to-expand-access-to-vevye